ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET
on Thursday, August 6, 2009 to discuss the Company’s financial results
for the three-month period and fiscal year ended June 30, 2009.
Management also will provide an update on the Company.
To access the live call by phone, dial 913-981-4900. No passcode is
required. The call also may be accessed through the Investor Information
section of the Company’s website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through August 13, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its
expertise in cancer biology, monoclonal antibodies and the creation and
linkage of potent cancer-cell killing agents (CKAs) to such antibodies.
The Company’s proprietary Targeted Antibody PayloadTM (TAP)
technology consists of ImmunoGen’s highly potent CKAs, which have been
designed specifically for delivery by antibodies to cancer cells, and
the Company’s engineered linkers, which direct the activation of the CKA
inside a cancer cell. Compounds utilizing the TAP technology are in
clinical testing through ImmunoGen’s own programs and its collaborations
with Genentech (a wholly-owned member of the Roche Group),
sanofi-aventis, Biogen Idec and Biotest. The most advanced compound,
trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by
Genentech and Roche. Other ImmunoGen collaborative partners include
Bayer HealthCare and Amgen.
ImmunoGen, Inc.
Carol Hausner, Executive Director, Investor
Relations and Corporate Communications, 781-895-0600
info@immunogen.com
